Company intelligence / Profile preview
SynaptixBio
Oxford, Oxfordshire, United Kingdomsynaptixbio.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Preclinical
01
Overview
SynaptixBio is developing a treatment for TUBB4A-related leukodystrophy, a rare genetic central nervous system disease. Their therapeutic assets are at a pre-clinical stage of development. The company has secured FDA Orphan Drug Designation and Rare Pediatric Designation for their drug candidate[3][7].
- Therapeutic areas
- Neurology
- Modalities
- Antisense oligonucleotides (ASOs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Children's Hospital of Philadelphia (CHOP)
Beyond the preview
Go deeper on SynaptixBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SynaptixBio.